- Phase I
- Phase II/III
- Therapeutic expertise
- Rescue services
- Technology solutions
- Comprehensive capabilities
- News &
Atopic Dermatitis Research Network (ADRN)
The Atopic Dermatitis Research Network (ADRN) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) conducts clinical trials/studies and animal studies to expand research begun under the Atopic Dermatitis and Vaccinia Network (ADVN). The research being conducted encompasses defense mechanisms of the skin (immune defenses and skin barrier function), genetics, immunopathogenesis (i.e. how the immune system operates in relation to the disease), susceptibility to infections, and responsiveness to vaccines.
Rho serves as the Statistical and Clinical Coordinating Center (SACCC) for the ADRN, providing support for the network’s clinical and animal studies. In this capacity, Rho is responsible for statistical design and data analysis, clinical coordination and project management, regulatory guidance, computer-based data collection and management, operational support, safety oversight and reporting, clinical site monitoring, and the establishment and maintenance of a registry of patients with atopic dermatitis.
Gloria David, Ph.D., M.H.Sc., is Principal Investigator (PI) of the ADRN SACCC. As a post-doctoral fellow for both the Johns Hopkins Department of Oncology and the National Institute of Environmental Health Sciences, Dr. David has received numerous professional honors for accomplishments in research related to cancer and respiratory disease. She is lead author in many peer-reviewed publications for research in lung, prostate, breast cancer, asthma, and other respiratory diseases.
For more information about this research from ClinicalTrials.gov, please see below.